IP Group, CIC and Johnson & Johnson have returned for a $52.2m series B round in Inivata, a spinout of Cancer Research UK and University of Cambridge.
Inivata, a UK-based oncology genomics technology spinout, closed a £39.8m ($52.2m) series B round today backed by Cambridge Innovation Capital (CIC), the patient capital affiliate of University of Cambridge.
Commercialisation firm IP Group also took part, as did Johnson & Johnson Innovation – JJDC, the healthcare group’s corporate venturing subsidiary, and Woodford Patient Capital Trust, operated by fund manager Woodford Investment Management.
RT Ventures also contributed to the round, which was oversubscribed and raised over two tranches. The…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
